An AI-designed vaccine against all variants of the coronavirus SARS-CoV-2 – designed using an AI-powered platform developed ...

And yet, ask most HCPs whether their experience of engaging with pharma has meaningfully improved, and the answer is usually ...

Parabilis Medicines has revealed the financial details behind its recently announced IPO, hoping to raise up to $475 million ...

Multiple sclerosis (MS) is undergoing a meaningful evolution in how it is understood, diagnosed, and managed. Advances in ...

Longevity start-up NewLimit has raised an eye-watering $435 million to take its lead age reprogramming candidate into human ...

A £600 million tranche of government funding for a key part of the UK's life sciences strategy – expanding the country's ...

Analysts suggested the deaths could overshadow the PFS results, and the safety trade-off may make it harder for ADC ...

Final draft guidance from reimbursement authority NICE recommends Elahere (mirvetuximab soravtansine) for treating ...

New trial data with Johnson & Johnson's nipocalimab, Biogen and UCB's dapirolizumab pegol, and Merck KGaA's enpatoran have ...

The Coalition for Epidemic Preparedness Innovations (CEPI) has made $60 million available for clinical trials of vaccines for ...

AstraZeneca has presented new data from the SERENA-6 trial of camizestrant in advanced breast cancer that it hopes will ...

Servier has signed the largest licensing deal in its history, paying $1.55 billion upfront for Edgewise Therapeutics' ...